For many pharmaceutical companies, particularly those entering the European market for the first time, a fully centralized hub is highly appealing. It offers potential economies of scale, unified oversight, harmonized reporting, and simplified coordination to support early launch activities. However, Europe remains a fragmented landscape of 27 European Union (EU) member states, each with its own laws, pricing regimes, and logistical infrastructures. As an organization matures, achieves sales growth, enters new markets, and faces increasing regulatory complexity, early centralization decisions must often be revisited. This inflection point signals the need for a shift toward localized or hybrid distribution to maintain efficient uninterrupted patient access and compliance.

This white paper is designed for pharmaceutical supply chain leaders seeking to navigate this complexity. It offers a set of guiding dimensions to assess when and how to localize distribution strategies. In the following sections, we will explore the regulatory drivers reshaping the landscape, delve into market and commercial considerations, and provide key strategic questions to help determine when a local approach makes the most strategic sense.